Equities Analysts Set Expectations for XOMA Co.’s Q1 2024 Earnings (NASDAQ:XOMA)

XOMA Co. (NASDAQ:XOMA) – Equities research analysts at Leerink Partnrs issued their Q1 2024 earnings per share estimates for shares of XOMA in a report issued on Monday, April 29th. Leerink Partnrs analyst D. Risinger expects that the biotechnology company will post earnings of ($0.85) per share for the quarter. Leerink Partnrs currently has a “Outperform” rating on the stock. The consensus estimate for XOMA’s current full-year earnings is ($2.11) per share. Leerink Partnrs also issued estimates for XOMA’s Q2 2024 earnings at ($0.79) EPS, Q3 2024 earnings at ($0.54) EPS, Q4 2024 earnings at ($0.69) EPS, FY2024 earnings at ($2.87) EPS, FY2025 earnings at ($1.63) EPS, FY2026 earnings at ($0.37) EPS, FY2027 earnings at $1.05 EPS and FY2028 earnings at $3.31 EPS.

XOMA (NASDAQ:XOMA) last posted its quarterly earnings data on Friday, March 8th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.13). XOMA had a negative net margin of 886.91% and a negative return on equity of 25.17%. The business had revenue of $1.83 million for the quarter, compared to analysts’ expectations of $1.01 million.

XOMA has been the subject of a number of other research reports. SVB Leerink began coverage on XOMA in a report on Monday, April 29th. They set an “outperform” rating and a $40.00 price objective for the company. HC Wainwright reiterated a “buy” rating and issued a $74.00 target price on shares of XOMA in a report on Wednesday.

XOMA Price Performance

XOMA opened at $24.78 on Thursday. The business has a fifty day moving average of $25.13 and a 200 day moving average of $20.77. XOMA has a 52-week low of $13.48 and a 52-week high of $27.00. The company has a quick ratio of 8.68, a current ratio of 8.68 and a debt-to-equity ratio of 1.34. The stock has a market cap of $288.44 million, a P/E ratio of -6.13 and a beta of 0.57.

Institutional Investors Weigh In On XOMA

A hedge fund recently raised its stake in XOMA stock. BNP Paribas Financial Markets lifted its stake in XOMA Co. (NASDAQ:XOMA) by 55.6% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,543 shares of the biotechnology company’s stock after acquiring an additional 1,266 shares during the period. BNP Paribas Financial Markets’ holdings in XOMA were worth $85,000 at the end of the most recent quarter. Institutional investors and hedge funds own 95.92% of the company’s stock.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.